VERA News

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine